CD137 antibody
Quick Overview for CD137 antibody (ABIN6938626)
Target
See all CD137 (TNFRSF9) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
No Cross-Reactivity
- Human
-
Purification
- Purified by Protein A/G
-
Immunogen
- Murine CD137 human Fc fusion protein
-
Isotype
- IgG2a kappa
-
-
-
-
Application Notes
-
Positive Control: MPBMC's or Thymus.
Known Application: Functional Studies (Order Antibody without BSA & Azide); Flow Cytometry (0.5-1ug/million cells in 0.1ml); Immunofluorescence (0.5-1ug/ml)Optimal dilution for a specific application should be determined.
-
Restrictions
- For Research Use only
-
-
-
Buffer
- 10 mM PBS without BSA and without Azide.
-
Preservative
- Azide free
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months.
-
Expiry Date
- 24 months
-
-
- CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))
-
Alternative Name
- TNFRSF9
-
Background
- CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, is a type I transmembrane glycoprotein expressed on the cell surface of activated splenic T cells and thymocytes. The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis. CD137 and CD28 are costimulatory molecules of T cell activation. Costimulatory molecules are important in initiating anti-tumor immune responses. CD137 plays an important role in regulating T-cell-dependent immune responses. Expression of CD137 correlates negatively with lymphocyte proliferation and positively with the degree of activation-induced cell death caused by mitogen overstimulation. In monocytes, CD137 induces activation, promotes adherence and prolongs survival. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growthin vivowhen administered in combination with immune checkpoint inhibitors.
-
Molecular Weight
- 39kDa
-
Gene ID
- 21942
-
UniProt
- P20334
-
Pathways
- Cancer Immune Checkpoints
Target
-